Conclusion
BACTERIAL INFECTIONS
Both IV and oral administrations of contezolid acefosamil demonstrated good safety and tolerability in healthy Chinese subjects, which can inform the safety, PK, and dose selection for the development of the phase III study of contezolid acefosamil. The new dosage form of contezolid acefosamil may be an effective and safer treatment option for patients with severe multidrug-resistant bacterial infections.